文献速递神经免疫

复发缓解型多发性硬化中不依赖复发活动的进展(PIRA)的标准化定义

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2025-01-01

结果显示PIRA发生率范围为0.141至0.658事件/十年,持续率范围为0.753至0.919,取决于所用定义;基线设定和确认期影响PIRA检测。作者提出一种平衡发生率和持续率的标准化定义以提高研究间可比性。

要点

  • PIRA发生率和持续率因定义不同而异,发生率0.141–0.658事件/十年,持续率0.753–0.919。
  • 基线和确认期的选择显著影响PIRA的检测。
  • 提出的标准化定义:残疾恶化较基线显著(每次PIRA事件、复发和EDSS改善后重置基线),自上次EDSS评估以来无复发,EDSS确认(前30天内无复发)且恶化阈值以上持续至少12个月。

核心结论

  • PIRA的发生率和持续率取决于所采用的定义,提出的标准化定义旨在增强研究间的可比性。

研究设计与样本

  • 本队列研究为回顾性分析,数据来自MSBase登记数据库2004年7月至2023年7月的前瞻性收集数据。
  • 纳入来自43个国家186个中心的33 303例临床确诊复发缓解型多发性硬化患者,具备完整最小数据集和3次以上EDSS评估。

主要发现

  • 在33 303例患者中,24 152例(72.5%)为女性,9151例(27.5%)为男性;首次访视时平均(SD)年龄36.4(10.9)岁;28 052例(84.2%)为复发缓解型多发性硬化,EDSS中位数(IQR)为2.0(1.0-3.0)。
  • 参与者平均(SD)访视15.1(11.9)次,随访8.9(5.2)年。
  • PIRA发生率范围为0.141至0.658事件/十年,持续率范围为0.753至0.919,取决于定义。
  • 基线和确认期影响PIRA检测。

关键数值与推荐

  • 提出的标准化定义:与基线(每次PIRA事件、复发和EDSS评分改善后重置)相比出现显著残疾恶化,自上次EDSS评估以来无复发,通过EDSS评分确认(前30天内无复发)且保持在恶化阈值以上至少12个月。

临床怎么用

  • 临床研究中采用统一的PIRA标准化定义可提高研究结果的可比性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. OBJECTIVE: To compare various definitions of PIRA. DESIGN, SETTING, AND PARTICIPANTS: This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. EXPOSURE: Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). MAIN OUTCOME AND MEASURE: For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years). RESULTS: Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. CONCLUSION AND RELEVANCE: Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Müller J, Sharmin S, Lorscheider J, et al. Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2025. PMID: 40227706. doi:10.1001/jamaneurol.2025.0495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。